Fecal Microbiota Transplantation
VIDEO: ‘Robust’ data analysis establishes safety of Rebyota for recurrent C. difficile
In a Healio video exclusive, Lindy Bancke, PharmD, outlines results from the “largest safety evaluation to date” for Rebyota, the first FDA-approved, microbiota-based treatment for prevention of recurrent Clostridioides difficile infection.
Microbiome rundown: Artificial sweeteners, exercise alter gut bacteria; FMT shows promise
Healio has kept an eye on the latest research regarding the gut microbiome’s role in gastrointestinal diseases and how the microbiota can be altered. Did you miss an update? Healio recaps notable data this year and what they mean for you.
FMT shows promise in restoring gut barrier function, immunity in cirrhosis
Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.
Fecal microbiota transplant may overcome resistance to anti-PD-1 therapy for solid cancers
CHICAGO — Fecal microbiota transplantation that contains effective microbiota may overcome resistance to anti-PD-1 therapy among patients with advanced solid cancers, according to data presented at ASCO Annual Meeting.
VIDEO: Rebyota safe, effective when given via colonoscopy for recurrent C. difficile
CHICAGO — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses data showing consistent safety and efficacy of Rebyota when administered via colonoscopy for prevention of recurrent Clostridioides difficile infection.
VIDEO: ‘We can feel confident’ in Rebyota for recurrent C. difficile in high-risk patients
CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.
Top in ID: ICU outbreak; oral therapy for recurrent CDI
A hospital that replaced sink drains and traps in an ICU, hoping to curtail an outbreak of Klebsiella pneumoniae carbapenemase-producing bacteria, instead saw patients infected in a new outbreak of Serratia marcescens, according to a study.
Novel alternative to fecal microbiota therapy prevents recurrent CDI in study
A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.
Top in ID: Effectiveness of masks against COVID-19; recurrent CDI treatment
A recent review of randomized controlled trials — most of which were conducted before the COVID-19 pandemic — has become part of the debate on the effectiveness of masks in preventing the spread of respiratory illnesses.
Bezlotoxumab, fecal microbiota transplant similarly effective in preventing recurrent CDI
Bezlotoxumab and fecal microbiota transplantation were similarly effective at preventing both early and late recurrent Clostridioides difficile infection, according to a study published in Open Forum Infectious Diseases.